Search research articles
Contact Us
Filters
Showing results (21-30 of 41) with videos related to
Page
of 5
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
September 18, 2025
Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort
Cyrille Hulin, Karim Belhadj Merzoug, Bruno Royer, et al.
Leukemia & Lymphoma
|
June 4, 2021
Waldenström macroglobulinemia and relationship to immune deficiency
Anthony Levy, Stéphanie Guidez, Céline Debiais, et al.
Journal of Thrombosis and Haemostasis : JTH
|
June 16, 2025
Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, et al.
Haematologica
|
August 28, 2025
Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study
Thomas Chalopin, Cyrille Hulin, Bruno Royer, et al.
Clinical Case Reports
|
May 19, 2023
Hairy cell leukemia with isolated bone lesions
Laura Cailly, Cécile Gruchet, Elsa Maitre, et al.
Oncotarget
|
May 31, 2018
Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma
Guillemette Fouquet, Stéphanie Guidez, Valentine Richez, et al.
Clinical Hematology International
|
September 22, 2025
Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study
Titouan Cazaubiel, Olivier Decaux, Bruno Royer, et al.
Blood Cancer Journal
|
December 18, 2024
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
Florent Malard, Arthur Bobin, Myriam Labopin, et al.
Cancer Medicine
|
March 15, 2025
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020
Laure Vincent, Olivier Decaux, Aurore Perrot, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 17, 2025
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study
Thomas Chalopin, Olivier Decaux, Cyrille Hulin, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 41) with videos related to
Sort By:
Page
of 5
Clinical Lymphoma, Myeloma & Leukemia
|
September 18, 2025
Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort
Cyrille Hulin, Karim Belhadj Merzoug, Bruno Royer, et al.
Leukemia & Lymphoma
|
June 4, 2021
Waldenström macroglobulinemia and relationship to immune deficiency
Anthony Levy, Stéphanie Guidez, Céline Debiais, et al.
Journal of Thrombosis and Haemostasis : JTH
|
June 16, 2025
Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, et al.
Haematologica
|
August 28, 2025
Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study
Thomas Chalopin, Cyrille Hulin, Bruno Royer, et al.
Clinical Case Reports
|
May 19, 2023
Hairy cell leukemia with isolated bone lesions
Laura Cailly, Cécile Gruchet, Elsa Maitre, et al.
Oncotarget
|
May 31, 2018
Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma
Guillemette Fouquet, Stéphanie Guidez, Valentine Richez, et al.
Clinical Hematology International
|
September 22, 2025
Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study
Titouan Cazaubiel, Olivier Decaux, Bruno Royer, et al.
Blood Cancer Journal
|
December 18, 2024
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
Florent Malard, Arthur Bobin, Myriam Labopin, et al.
Cancer Medicine
|
March 15, 2025
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020
Laure Vincent, Olivier Decaux, Aurore Perrot, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 17, 2025
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study
Thomas Chalopin, Olivier Decaux, Cyrille Hulin, et al.
Page
of 5